Sunvozertinib’s Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory NSCLC with EGFR exon20ins. An ongoing randomized global Phase III study (WU-KONG28) is assessing sunvozertinib versus platinum…